Natera, Inc., a company involved in cell-free DNA testing, has entered into an agreement with Merck & Co., under which Merck will utilize Natera’s real-world database (RWD) to advance oncology research. Natera’s oncology RWD contains de-identified clinical and genomic data from more than 100,000 early- and late-stage patients with cancer who have been tested with Signatera, the company’s personalized and tumor-informed molecular residual disease (MRD) test. Longitudinal monitoring data is...